# OnCo record dbc-664 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/dbc-664/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "dbc-664" ;
  schema:name "DBC-664"@en ;
  schema:description "DBC-664 is an experimental bispecific T-cell engager antibody from Duboce Biopharmaceuticals, in phase 1 trials for ovarian adenocarcinoma, endometrial adenocarcinoma and malignant germ cell tumours and other cancers."@en ;
  schema:url <https://onco.cc/drugs/dbc-664/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.tcglsoleil.com/news/tcg-labs-soleil-highlights-portfolio-momentum-with-three-programs-entering-first-in-human-clinical-trials-across-oncology-and-cardiovascular-disease/>, <https://clinicaltrials.gov/api/v2/studies/NCT07705035>, <https://clinicaltrials.gov/search?intr=DBC-664> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Bispecific T-cell engager antibody" ;
  onco:cancers <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/endometrial/>, <https://onco.cc/cancers/lung-adenocarcinoma/>, <https://onco.cc/cancers/gastric/>, <https://onco.cc/cancers/urothelial/> ;
  onco:targets <https://onco.cc/targets/cd3/> ;
  onco:companies <https://onco.cc/companies/duboce-biopharmaceuticals/> ;
  onco:trials <https://onco.cc/trials/nct07705035/> .